Image 1 of 1

080207_galapagos_201.jpg

Add to Cart Add to Lightbox Download
Galapagos N.V. Pharmaceutical laboratory in Mechelen, Belgium. Galapagos has developed a target discovery platform that provides novel starting points for drug and antibody therapies, thereby addressing the industry's need for innovative, disease-modifying medicines. The Company's product portfolio consists mainly of new mode-of-action drugs in bone and joint diseases as well as programs in bone metastasis and cachexia. To enable the progression of a broad portfolio of programs, Galapagos has established risk sharing alliances with big pharma companies such as Johnson and Johnson, GlaxoSmithkline and Roche, and Janssen Pharmaceutica, in specific disease areas. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases. Galapagos' service division BioFocus based in the United Kingdom, offers a full suite of target-to-drug discovery products and services to pharma, biotech and patient foundations - encompassing target and drug discovery through to the delivery of pre-clinical candidates. (Photo © Jock Fistick)
Copyright
JOCK FISTICK
Image Size
5120x3407 / 3.4MB
Contained in galleries
Galapagos / Biofocus
Galapagos N.V. Pharmaceutical laboratory in Mechelen, Belgium. Galapagos has developed a target discovery platform that provides novel starting points for drug and antibody therapies, thereby addressing the industry's need for innovative, disease-modifying medicines. The Company's product portfolio consists mainly of new mode-of-action drugs in bone and joint diseases as well as programs in bone metastasis and cachexia. To enable the progression of a broad portfolio of programs, Galapagos has established risk sharing alliances with big pharma companies such as Johnson and Johnson, GlaxoSmithkline and Roche, and Janssen Pharmaceutica, in specific disease areas. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases. Galapagos' service division BioFocus based in the United Kingdom, offers a full suite of target-to-drug discovery products and services to pharma, biotech and patient foundations - encompassing target and drug discovery through to the delivery of pre-clinical candidates. (Photo © Jock Fistick)